
Oxford BioMedica makes management change
pharmafile | February 10, 2012 | Appointment | Research and Development, Sales and Marketing | Oxford BioMedica
Gene-based biopharmaceutical firm Oxford BioMedica has announced that Andrew Wood, chief financial officer, has stepped down from the board of Oxford BioMedica.
Tim Watts (pictured) has been appointed to the board as chief financial officer and company secretary of Oxford BioMedica with immediate effect. Andrew will continue as an employee of the company for the time being to ensure the smooth transition of the role.
Tim is a senior financial executive with over 30 years’ experience in leading multinational and entrepreneurial businesses. He was most recently chief financial officer at Archimedes Pharma, an international speciality pharma company.
Following the merger of Astra and Zeneca, Tim became group financial controller of AstraZeneca in 2001. In 2007 he left AstraZeneca to become chief financial officer at Archimedes Pharma.
John Dawson, chief executive of Oxford BioMedica, said: “We thank Andrew for his substantial contribution to Oxford BioMedica since its IPO in 1996. His commitment to the Company has been invaluable and we wish him well for the future. I would like to welcome Tim to the executive management team and am confident that his expertise will support Oxford BioMedica’s strategy to secure corporate and commercial success.”
Related Content

Oxford Biomedica acquires ABL Europe for €15m
Oxford Biomedica has announced that it has completed the acquisition of ABL Europe from Institut …

Oxford Biomedica joins forces with UK’s Vaccines Manufacturing and Innovation Centre to scale up production of Oxford Uni’s COVID-19 vaccine
Oxford Biomedica has forged a five-year partnership with the Vaccines Manufacturing and Innovation Centre (VMIC) …

Novo Holdings invests £53.5 million into Oxford Biomedica
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for …






